埃万妥单抗联合兰泽替尼重塑EGFR经典突变晚期NSCLC一线治疗格局，为患者带来生存获益。

*以下内容仅供医疗卫生专业人士浏览。

打开网易新闻 查看精彩图片
打开网易新闻 查看精彩图片

参考文献：

[1]中国临床肿瘤学会非小细胞肺癌专家委员会,PACC专家共识编写小组.EGFR PACC突变晚期非小细胞肺癌诊疗专家共识（2025版）[J].中华肿瘤杂志,2025,47(9):811-829.

[2]Cho BC,Lu S,Felip E,et al.Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.N Engl J Med.2024 Oct 24;391(16):1486-1498.

[3]Shirish MG,et al.Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC:Longer Follow-up of the MARIPOSA Study.2024 WCLC.OA.02.03.

[4]Yang JC,et al.MARIPOSA Investigators.Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.N Engl J Med.2025 Sep 7.

[5]NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®)Non-Small cell LungCancer Version 8.2025.

[6]中国临床肿瘤学会（CSCO）非小细胞肺癌（NSCLC）诊疗指南（2025年）.

[7]Lu S,Byoung CC,Jong-Seok L,et al.Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated,Advanced Non-small Cell Lung Cancer(NSCLC):MARIPOSA Subgroup Analysis.2023 ESMO Aisa.LBA10.

[8]Felip E,et al.Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease:a secondary analysis from MARIPOSA.Ann Oncol.2024;35(9):805-816.

[9]Cho BC,Li W,Spira AI,et al.Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC:The COCOON Global Randomized Controlled Trial.J Thorac Oncol.2025 Oct;20(10):1517-1530.

[10]Spira AI,Paz-Ares L,Han JY,et al.Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr,a Phase 2 Study:A Brief Report.J Thorac Oncol.Published online January 24,2025.

审批编码：CP-556676

批准分发日期：12/9/2025

有效期：12/9/2026

*“医学界”力求所发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。